论文部分内容阅读
目的观察直肠癌术中局部植入氟尿嘧啶缓释剂(5-FU SRI)的可行性及疗效。方法 92例直肠癌患者分成治疗组和对照组,治疗组术中在瘤床和沿淋巴引流途径分多点植入5-FU SRI 600 mg,对照组行常规直肠癌根治术,观察2组患者的手术情况、毒副反应、近期并发症及远期疗效。结果 2组的手术时间、出血量以及腹膜炎、吻合口漏、肠梗阻和切口感染发生率的差异均无统计学意义(P>0.05);2组患者的白细胞计数、肌酐及ALT水平治疗后高于治疗前(P<0.05),但2组间差异无统计学意义(P>0.05)。治疗组腹腔局部复发率及远处转移率均较对照组低(P<0.05)。结论直肠癌术中植入5-FU SRI是安全可行的,是预防术后复发转移的有效途径。
Objective To observe the feasibility and efficacy of locally implanted fluorouracil sustained-release agent (5-FU SRI) in rectal cancer. Methods Ninety-two patients with rectal cancer were divided into treatment group and control group. The operation group received 5-FU SRI 600 mg subcutaneously in the tumor bed and lymphatic drainage and the control group underwent conventional radical rectal cancer. The patients in two groups The operation, side effects, recent complications and long-term efficacy. Results There was no significant difference in operative time, bleeding volume, peritonitis, anastomotic leakage, intestinal obstruction and incision infection between the two groups (P> 0.05). The white blood cell count, creatinine and ALT levels were significantly higher in the two groups Before treatment (P <0.05), but no significant difference between the two groups (P> 0.05). The local recurrence rate and distant metastasis rate in the treatment group were lower than those in the control group (P <0.05). Conclusion Intraoperative implantation of 5-FU SRI in rectal cancer is safe and feasible, which is an effective way to prevent recurrence and metastasis.